Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Brenda Canty - Johnson & Johnson Laboratories

Pharma 2020 – trends that are shaping the industry

  • Login to see the comments

Brenda Canty - Johnson & Johnson Laboratories

  1. 1. 1 Pharma 2020 – trends that are shaping the industry Brenda Canty Senior Manager, Johnson & Johnson Labs
  2. 2. 2 There are still many opportunities despite significant and growing challenges • Economic environment • Regulatory pressures • Innovation threshold • External barriers to innovation • Competition Ongoing Challenges • Significant unmet needs • Personalized solutions • Aging demographics • Large under-served populations • Mobile populations • Global warming Future Drivers 2
  3. 3. 3 A growth market…. Ageing populations Terminal Diseases Chronic Developed & Same diseases Developing countries Emerging markets more affluent Leading cause of death now chronic disease (e.g. diabetes) Global warming Global weather patterns, Man-made pollutants, Vector borne diseases Drug resistance New anti-infectives
  4. 4. 4 The bottom line… Pharma operations Innovation slow & expensive Market value slowing down Industrialise R&D package products & services, target specific disease Incentivise R&D change legal & political framework to promote innovation
  5. 5. 5 The bottom line… Cost of treatment Costs unsustainable Cost risks of prevention different to treatment Governments reverse approach Blurring healthcare Boundaries
  6. 6. 6 By 2020, the pharmaceutical, payer & provider value chains will be more integrated
  7. 7. 7 The bottom line… Cost of treatment Costs unsustainable Cost risks of prevention different to treatment Governments reverse approach Blurring healthcare Pharma focus on providing full Boundaries range of services spanning healthcare spectrum Shift towards Pay-for-performance, not outcomes treatment Help patients comply
  8. 8. 8 Major changes anticipated Health care will shift in focus from treatment to prevention. Pharmaceutical companies will provide total health care packages. The current linear phase research & development process will give way to in-life testing and live licensing, in collaboration with regulators and health care providers.
  9. 9. 9 Major changes anticipated The traditional blockbuster sales model will disappear. The supply chain function will become revenue generating as it becomes integral to the health care package and enables access to new channels. More sophisticated direct-to-consumer distribution channels will diminish the role of wholesalers.
  10. 10. 10 By 2020, the Pharma business model will have changed significantly Source: PwC
  11. 11. 11 Fully diversified business model
  12. 12. 12 Implications for labs – layout & design Labs 2015 Labs of the future
  13. 13. 13 Implications for labs - technology Tech 2015 Tech of the future
  14. 14. 14 Implications for labs - analysts Tech 2015 Tech of the future
  15. 15. 15 What capabilities, competencies & talent do we need to achieve this? Shape the external environment New quality frameworks Build Quality into lifecycle design Scalable to help the business grow Customer/market insights Connect with customers and stakeholders Understand our & their needs Regional capacities & expertise Serve emerging markets • Strong people leaders • Business acumen • Creative thinkers • Balanced risk taking (venturing) • Ideation techniques • Multi-lingual skills • Strong data analytics • Broad cross-quality knowledge • Cross-functional agility • Multi-sector experience • Strong influencers & relationship builders • Expertise in new technical areas • Change agent mentality • Project management • Multi-cultural awareness Capabilities Talent & Competencies
  16. 16. 16 The future is promising, but not promised…
  17. 17. 17 Q&A 1Confidential – For Internal Use Only